|
|
|
ADMET Regression Property
|
| ADMET Type |
Classification |
Endpoint |
Value |
Percentile |
Histogram |
Info |
| Absorption |
Oral Bioavailability |
Caco-2 |
NA
|
NA |
|
ⓘ
|
| Absorption |
Lipophilicity & Solubility |
Hydration Free Energy |
NA |
NA |
|
ⓘ
|
| Absorption |
Lipophilicity & Solubility |
Lipophilicity |
NA |
NA |
|
ⓘ
|
| Absorption |
Lipophilicity & Solubility |
Solubility |
-4.65 |
14.33% |
|
ⓘ
|
| Distribution |
Protein Binding |
PPB |
NA |
NA |
|
ⓘ
|
| Distribution |
Tissue Distribution |
VDss |
NA |
NA |
|
ⓘ
|
| Distribution |
Tissue Distribution |
PPBR |
NA |
NA |
|
ⓘ
|
| Excretion |
Clearance & Half-life |
T1/2 |
NA |
NA |
|
ⓘ
|
| Excretion |
Clearance & Half-life |
MRT |
NA |
NA |
|
ⓘ
|
| Excretion |
Clearance & Half-life |
logCL(ml/min/k) |
NA |
NA |
|
ⓘ
|
| Excretion |
Clearance & Half-life |
Clearance |
NA |
NA |
|
ⓘ
|
| Toxicity |
Acute & Repeated Dose |
Acute oral toxicity |
NA |
NA |
|
ⓘ
|
| Toxicity |
Acute & Repeated Dose |
FDAMDD |
NA |
NA |
|
ⓘ
|
| Toxicity |
Carcinogenicity |
Mouse carcinogenicity |
NA |
NA |
|
ⓘ
|
| Toxicity |
Carcinogenicity |
Rat carcinogenicity |
NA |
NA |
|
ⓘ
|
| Toxicity |
Ecotoxicity |
T. pyriformis toxicity |
NA |
NA |
|
ⓘ
|
| Toxicity |
Ecotoxicity |
BCF |
NA |
NA |
|
ⓘ
|
| Toxicity |
Organ Toxicity |
Neurotoxicity |
NA |
NA |
|
ⓘ
|
|
|
------------------------------------------------------------------------------------
|
|
|
|
|
|
|
|
|
ADMET Classification Property
|
| ADMET Type |
Classification |
Endpoint |
Value |
Sign |
Proportion |
Info |
| Absorption |
Oral Bioavailability |
F50% |
NA |
● |
NA |
ⓘ
|
| Absorption |
Oral Bioavailability |
F30% |
NA |
● |
NA |
ⓘ
|
| Absorption |
Oral Bioavailability |
F20% |
NA |
● |
NA |
ⓘ
|
| Absorption |
Oral Bioavailability |
Bioavailability |
NA |
● |
NA |
ⓘ
|
| Absorption |
Permeability |
PAMPA |
0 |
●
|
37.77% |
ⓘ
|
| Absorption |
Permeability |
HIA |
NA |
● |
NA |
ⓘ
|
| Absorption |
Permeability |
MDCK |
NA |
● |
NA |
ⓘ
|
| Distribution |
Tissue Distribution |
BBB |
1 |
●
|
69.73% |
ⓘ
|
| Metabolism |
CYP450 Enzymes |
CYP3A4 substrate |
1 |
●
|
55.7% |
ⓘ
|
| Metabolism |
CYP450 Enzymes |
CYP2C9 substrate |
0 |
●
|
67.07% |
ⓘ
|
| Metabolism |
CYP450 Enzymes |
CYP2C19 substrate |
1 |
●
|
61.97% |
ⓘ
|
| Metabolism |
CYP450 Enzymes |
CYP2D6 substrate |
1 |
●
|
33.46% |
ⓘ
|
| Metabolism |
CYP450 Enzymes |
CYP1A2 inhibitor |
NA |
● |
NA |
ⓘ
|
| Metabolism |
CYP450 Enzymes |
CYP3A4 inhibitor |
NA |
● |
NA |
ⓘ
|
| Metabolism |
CYP450 Enzymes |
CYP2B6 inhibitor |
NA |
● |
NA |
ⓘ
|
| Metabolism |
CYP450 Enzymes |
CYP2C9 inhibitor |
NA |
● |
NA |
ⓘ
|
| Metabolism |
CYP450 Enzymes |
CYP2C19 inhibitor |
NA |
● |
NA |
ⓘ
|
| Metabolism |
CYP450 Enzymes |
CYP2D6 inhibitor |
NA |
● |
NA |
ⓘ
|
| Metabolism |
CYP450 Enzymes |
CYP1A2 substrate |
NA |
● |
NA |
ⓘ
|
| Metabolism |
CYP450 Enzymes |
CYP2B6 substrate |
NA |
● |
NA |
ⓘ
|
| Metabolism |
CYP450 Enzymes |
CYP2C9i inhibitor |
NA |
● |
NA |
ⓘ
|
| Metabolism |
Hepatic Stability |
HLM |
NA |
● |
NA |
ⓘ
|
| Metabolism |
Hepatic Stability |
RLM |
NA |
● |
NA |
ⓘ
|
| Metabolism |
Hepatic Stability |
UGT substrate |
NA |
● |
NA |
ⓘ
|
| Excretion |
Clearance & Half-life |
CLp |
1 |
●
|
93.54% |
ⓘ
|
| Excretion |
Clearance & Half-life |
CLr |
NA |
● |
NA |
ⓘ
|
| Excretion |
Transporters |
OATP1B1 inhibitor |
1 |
●
|
90.71% |
ⓘ
|
| Excretion |
Transporters |
OATP1B3 inhibitor |
1 |
●
|
93.59% |
ⓘ
|
| Excretion |
Transporters |
P-gp inhibitor |
0 |
●
|
67.51% |
ⓘ
|
| Excretion |
Transporters |
OATP2B1 inhibitor |
NA |
● |
NA |
ⓘ
|
| Excretion |
Transporters |
OCT1 inhibitor |
NA |
● |
NA |
ⓘ
|
| Excretion |
Transporters |
OCT2 inhibitor |
NA |
● |
NA |
ⓘ
|
| Excretion |
Transporters |
BCRP inhibitor |
NA |
● |
NA |
ⓘ
|
| Excretion |
Transporters |
BSEP inhibitor |
NA |
● |
NA |
ⓘ
|
| Excretion |
Transporters |
MATE1 inhibitor |
NA |
● |
NA |
ⓘ
|
| Excretion |
Transporters |
P-gp substrate |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Acute & Repeated Dose |
Repeated dose toxicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Carcinogenicity |
Rodents carcinogenicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Cardiotoxicity |
hERG(1μM) |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Cardiotoxicity |
hERG(10μM) |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Cardiotoxicity |
hERG(30μM) |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Cardiotoxicity |
hERG(<1μM >10μM) |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Cardiotoxicity |
hERG(<10μM >30μM) |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Cellular Toxicity |
Mitochondrial toxicity |
0 |
●
|
76.99% |
ⓘ
|
| Toxicity |
Cellular Toxicity |
MMP |
0 |
●
|
83.73% |
ⓘ
|
| Toxicity |
Cellular Toxicity |
Hemolytic toxicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Cellular Toxicity |
Lysosomal toxicity (Phospholipidosis) |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Cytotoxicity |
RPMI_8226 Immunitoxicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Cytotoxicity |
HEK293 |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Cytotoxicity |
NIH3T3 |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Cytotoxicity |
CRL-7250 |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Ecotoxicity |
Honey bee toxicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Ecotoxicity |
Avian toxicity (Colinus virginanus) |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Ecotoxicity |
Avian toxicity (Anas platyrhynchos) |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Ecotoxicity |
P. subcapitata toxicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Ecotoxicity |
Crustaceans toxicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Ecotoxicity |
D. magna toxicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Ecotoxicity |
Fish toxicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Ecotoxicity |
Fathead minnow toxicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Ecotoxicity |
Bluegill sunfish toxicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Ecotoxicity |
Rainbow trout toxicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Ecotoxicity |
Sheepshead minnow toxicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Ecotoxicity |
Biodegradability |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Endocrine Disruption |
ER |
1 |
●
|
8.42% |
ⓘ
|
| Toxicity |
Endocrine Disruption |
Aromatase |
0 |
●
|
85.82% |
ⓘ
|
| Toxicity |
Endocrine Disruption |
AhR |
0 |
●
|
90.08% |
ⓘ
|
| Toxicity |
Endocrine Disruption |
ARE |
1 |
●
|
19.11% |
ⓘ
|
| Toxicity |
Endocrine Disruption |
ATAD5 |
0 |
●
|
94.42% |
ⓘ
|
| Toxicity |
Endocrine Disruption |
HSE |
0 |
●
|
94.78% |
ⓘ
|
| Toxicity |
Endocrine Disruption |
p53 |
0 |
●
|
91.23% |
ⓘ
|
| Toxicity |
Endocrine Disruption |
AR |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Endocrine Disruption |
AR-LBD |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Endocrine Disruption |
ER-LBD |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Endocrine Disruption |
PPAR-γ |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Endocrine Disruption |
TR |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Endocrine Disruption |
GR |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Genotoxicity |
Ames mutagenesis |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Genotoxicity |
Micronucleus |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Organ Toxicity |
DILI |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Organ Toxicity |
Respiratory toxicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Organ Toxicity |
Nephrotoxicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Organ Toxicity |
Ototoxicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Photoinduced Toxicity |
Photoinduced toxicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Photoinduced Toxicity |
Phototoxicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Photoinduced Toxicity |
Photoallergy |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Reproductive Toxicity |
Reproductive toxicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Skin & Eye Toxicity |
Eye corrosion |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Skin & Eye Toxicity |
Eye irritation |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Skin & Eye Toxicity |
Skin corrosion |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Skin & Eye Toxicity |
Skin irritation |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Skin & Eye Toxicity |
Skin sensitisation |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Skin & Eye Toxicity |
Acute dermal toxicity |
NA |
● |
NA |
ⓘ
|
| Toxicity |
Skin & Eye Toxicity |
HaCaT dermatotoxicity |
NA |
● |
NA |
ⓘ
|
|
|
------------------------------------------------------------------------------------
|
|
|
|
|
|
|
|